Cardiovascular Risk Factors in Middle Eastern Patients With Stroke (JoSMMART)

Standard Modifiable Risk Factors in Middle Eastern Patients With Stroke (Jo-SMMART Study)

Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.

Study Overview

• Status: Not yet recruiting
• Conditions: Stroke; Risk Factors; Low-Density-Lipoprotein-cholesterol Level

Detailed Description

Stroke is a well-known a leading cause of death and disability in the Middle East. There remain many knowledge gaps in evaluating the prevalence of risk factors among patients with stroke in the Middle East. Unravelling the impact of these risk factors and controlling them can positively lower the incidence of stroke. Disparities in stroke risk factors, may well be related to ethnicity of the Middle Eastern populations , will be compared with those among stroke patients in the western literature.

These clinically relevant issues have not been studied extensively in the Middle East where most of the studies in atherosclerotic cardiovascular disease have focused on acute coronary syndrome more than stroke. Exploring new information on risk factors of stroke in this region that helps fill some of the knowledge gaps.

Stroke has been attributed, in the majority of cases, to the traditional four standard modifiable risk factors of hypertension, type 2 diabetes, dyslipidemia, and cigarette smoking. However, ethnicity and geography account for the interregional differences of the prevalence of risk factors in patients with stroke.

The Jo-SMMART ill evaluate risk factors in 2000 stroke patients in Jordan as a representative of the Middle Eastern population, the prevalence of those with none of the 4 risk factors and the differences in clinical profiles and demographic features on those with risk factors and those with no risk factors. Lipid profile and use of lipid lowering agents will also be evaluated, and furthermore the die0fferneces between young vs old, and men vs women stroke patients ill be addressed.

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Ayman Hammoudeh, MD, FACC; Phone Number: 065001000; Email: hammoudeh_ayman@yahoo.com
• Study Contact Backup: Name: Laith Habahbeh, MD; Phone Number: 065001000; Email: a.hammoudeh@istisharihospital.com

Study Locations

• Jordan
  • Amman, Jordan, 11184
    • Istishari Hospital
    • Contact: Laith Habahbeh, MD; Phone Number: 065001000; Email: hammoudeh_ayman@yahoo.com
    • Contact: Ayman Hammoudeh, MD, FACC, FSCAI; Phone Number: 065001000; Email: hammoudeh_ayman@yahoo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Will enroll adults admitted to the hospital with a working diagnosis of stroke and then the diagnosis is confirmed by a neurologist. Patients ii be interviewed for data collection of 4 risk factors as above in addition to the serum level of LDLC and the use of lipid lowering agents.

Description

Inclusion Criteria:

• Diagnosis of stroke upon admission to the hospital
• Adult aged 18 years or older
• Available lipid profile on hospital admission

Exclusion Criteria:

• Stroke diagnosis unconfirmed
• age younger than 18 years
• No available lipid profile on admission

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of hypertension in stroke patients (survey interview)	BP more 140/90 or known diagnosis of high blood pressure or patient already on blood pressure medication	Baseline
Prevalence of type 2 diabetes in stroke patients (survey interview)	HbA1c more than 6.5%, or known diagnosis of type 2 diabetes or patient already on anti diabetes medications	BASELINE
Prevalence of elevated serum level of low density lipoprotein cholesterol in stroke patients (survey interview)	Elevated serum level of low density lipoprotein cholesterol > 55 mg/dl or patient already on lipid lowering medication	BASELINE
Prevalence of current cigarette smoking in stroke patients (survey interview)	Known current cigarette smoking of any number of cigarettes per day	BASELINE
Use of lipid lowering therapy (survey interview)	Current use of statin, ezitimibe, PCS9 inhibitor of small interfering RNA agent to lower the LDL-C	BASELINE

Collaborators and Investigators

• Sponsor: Jordan Collaborating Cardiology Group

Study record dates

Study Major Dates

• Study Start (Estimated): December 31, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): January 31, 2027

Study Registration Dates

• First Submitted: November 26, 2025
• First Submitted That Met QC Criteria: December 22, 2025
• First Posted (Actual): December 23, 2025

Study Record Updates

• Last Update Posted (Actual): December 23, 2025
• Last Update Submitted That Met QC Criteria: December 22, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Stroke; Risk factors
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke
• Other Study ID Numbers: JOCVA1.NOV2025/2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All individual participant data will be available in the form of excel sheet with no disclosure of patients names. Can be requested from the study director

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No